• "Market-leading firm representing high-profile domestic and international clients."

     

    Chambers Europe 2016

  • "the team understands our business and technology which is very useful when negotiating licenses and contracts"

     

    Client in Chambers Europe 2015

  • "Enjoys a sterling reputation for its breadth of practice, which includes transactions, litigation and regulatory issues."

     

    Chambers Europe 2016

  • "provides accurate sector knowledge"

     

    The Legal 500 2015

  • "regularly instructed on significant transactions"

     

    Chambers Europe 2015

  • "accurate sector knowledge"

     

    Legal 500 2016

  • "leverages superb corporate expertise"

     

    Chambers Europe 2015

  • "Quality-wise, the lawyers are very good and also very pragmatic in the way that they work and communicate with clients."

     

    Client in Chambers Europe 2016

  • "helps to find the right solution for the client"

     

    Legal 500 2016

  • "the collaboration was very good and the team managed things well"

     

    Client in Chambers Europe 2015

  • "increasingly strong reputation for regulatory advice"

     

    Chambers Europe 2015

 

 

 

Life Sciences

 

Our firm has extensive experience advising Swiss companies and subsidiaries of international groups on life sciences and health care matters.

 

Our life sciences team advises on regulatory issues and on the promotion and advertisement of drugs. We represent our clients in administrative investigations and proceedings as well as in litigation and arbitration. We draft and negotiate agreements relating to the development and distribution of pharmaceutical products as well as the use of the intellectual property on which they rely.

 

  • Regulatory advice
  • Advice regarding the promotion and advertising of drugs and medical devices
  • Representation in administrative investigations and proceedings as well as in court litigations and arbitrations
  • Research, development, licensing, collaboration, marketing and distribution agreements
  • Due diligence services and assistance in transactions involving undertakings of the life sciences and health care industry

 

 

 

Key Contact

 

IP, Licensing, R&D and Distribution

Dr. Markus Wang

Partner

Regulatory, Litigation


 

Team Leaders


 

Team Members

Raphael Wyss

Trainee

Lawyers Search





A B C D E F G H J K L M N O P Q R S T V W Z

Deals & Cases

16.01.2017
Bär & Karrer Advises Priora on Acquisition of Large Minority Stake in Galenica more »
08.12.2016
Bär & Karrer Advises EQT on the Acquisition of Fertin Pharma more »
31.10.2016
Bär & Karrer Advises Auven Therapeutics on Sale of Ocular Technologies to Sun Pharmaceutical Industries more »
more deals & cases

Publications

New Regulations Regarding Drug Pricing
Schott Markus / Wang Markus,

Bär & Karrer Briefing February 2017

Download »
The Life Sciences Law Review - Switzerland
Schott Markus / Wang Markus, in: Richard Kingham (eds.), The Life Sciences Law Review 4th edition, London 2016, p. 501-513 Download »
Environment & Climate Change Law 2016 - Switzerland
Schott Markus, ICLG - The International Comparative Legal Guide, p. 225 - 231 Download »
more publications